advanced enzymes
Where ENZYME is Life

Advanced Enzyme Technologies Ltd.
CIN: L24200MH1989PLC051018
Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India
Tel: +91-22-4170 3200
Email: info@advancedenzymes.com, www.advancedenzymes.com

August 08, 2026

BSE Limited
P. J. Towers,
Dalal Street,
Mumbai- 400 001

Scrip Code-540025

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (E) Mumbai- 400 051

Trading Symbol-ADVENZYMES

Dear Sir,

Subject: Outcome of Board Meeting held on August 08, 2026
Ref: ISIN: INE837H01020

With reference to the notice of the Board Meeting dated August 01, 2026, we hereby inform that the Board of Directors at its Meeting held on August 08, 2026 (commenced at 10.00 a.m. and concluded at 11.15 a.m.) has *inter alia*, transacted the following business:

- Approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.

  Please find enclosed herewith the above mentioned Financial Results along with the Limited Review Report from the Statutory Auditors as **Annexure – I.**

- Approved the Buyback of fully paid-up equity shares having a face value of ₹ 2/- (Rupees Two only) each of the Company at a price not exceeding ₹ 500/- (Rupees Five Hundred only) per equity share ("**Maximum Buyback Price**") and for an aggregate amount not exceeding ₹ 697,000,000 (Rupees Six Hundred and Ninety Seven Million only) ("**Maximum Buyback Size**"), from the shareholders of the Company (other than the Promoters, the Promoter group and Persons in control of the Company) payable in cash via "Open Market" route through the Stock Exchange mechanism in accordance with the provisions under the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended ("**Buyback Regulations**") and the Companies Act, 2013 and Rules made thereunder, as amended, and other applicable provisions thereunder.

  At the Maximum Buyback Size and the Maximum Buyback Price as mentioned above, the indicative maximum number of equity shares to be bought back under the Buyback would be 1,394,000 Equity Shares ("**Maximum Buyback Shares**") (representing 1.24% which is less than 25% of the existing paid up equity capital of the Company). The Maximum Buyback Size represents 9.99% and 5.09% of the aggregate of the total paid-up equity share capital and free reserves of the Company based on the latest audited Standalone and Consolidated financial statements of the Company

ADVANCED ENZYME TECHNOLOGIES LIMITED THANE

advanced enzymes
Where ENZYME is Life

Advanced Enzyme Technologies Ltd.
CIN: L24200MH1989PLC051018
Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India
Tel: +91-22-4170 3200, Fax: +91-22-2583 5159
Email: info@advancedenzymes.com, www.advancedenzymes.com

as on March 31, 2026, respectively. If the Equity Shares bought back at a price below the Maximum Buyback Price, the actual number of Equity Shares could exceed the indicative Maximum Buyback Shares (assuming full deployment of Maximum Buyback Size) but will always be subject to the Maximum Buyback Size.

Maximum Buyback Size shall not include any expenses to be incurred for the Buyback such as filing fees payable to SEBI, Stock Exchanges' fee for usage of their platform for Buyback, brokerage, applicable taxes such as securities transaction tax, Goods and Services Tax, stamp duty, etc., public announcement publication expenses, intermediaries' fees, printing and dispatch expenses and other incidental and related expenses ("Transactions Cost").

The Board has also constituted a committee for the purposes of the Buyback (the "Buyback Committee") and has delegated its powers to the Buyback Committee to do or cause to be done all such acts, deeds, matters and things, in its discretion, deem necessary in connection with the Buyback.

The public announcement setting out the process, timelines and other statutory details of the Buyback will be released in due course, in accordance with the Buyback Regulations.

- Approved acquisition of the remaining stake of 4.28% Equity Shares from the other existing Shareholders of JC Biotech Private Limited ("JCB") (Existing Subsidiary with 95.72% holding). Upon completion of this acquisition, JCB will become a Wholly Owned Subsidiary of the Company.

- Approved infusion of additional funds not exceeding ₹ 20 million, in one or more tranches, in Advanced Nutrazyme Private Limited ("ANPL") (Wholly Owned Subsidiary of the Company) by way of Equity investment or by providing inter corporate deposit pursuant to the provisions of the Companies Act, 2013, as may be amended from time to time.

In view of the aforesaid and pursuant to the provisions of Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (**"SEBI Listing Regulations"**) read with Master Circular HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated July 11, 2023 as amended, on January 30, 2026, the following Annexures are enclosed:

- Buyback of Equity Shares of the Company - **Annexure II.**

- Acquisition of Equity Shares of JCB and further infusion of funds in ANPL – **Annexure III.**

ADVANCED ENZYME TECHNOLOGIES LIMITED THANE

advanced enzymes
Where ENZYME Is Life

Advanced Enzyme Technologies Ltd.
CIN: L24200MH1989PLC051018
Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India
Tel: +91-22-4170 3200
Email: info@advancedenzymes.com, www.advancedenzymes.com

The aforesaid financial results and other documents are also being uploaded on the website of the Company i.e. www.advancedenzymes.com

This is for your information and for public at large.

Thanking you,
Yours faithfully,
For Advanced Enzyme Technologies Limited

Sanjay Basantani
Company Secretary and Head – Legal

ADVANCED ENZYME TECHNOLOGIES LIMITED
THANE

Encl.: As above

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

HO
602, Floor 6, Raheja Titanium
Western Express Highway, Geetanjali
Railway Colony, Ram Nagar, Goregaon (E)
Mumbai 400063, INDIA
Tel: +91 22 6974 0200

Independent Auditor's Review Report on consolidated unaudited financial results of Independent Auditor's for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Advanced Enzyme Technologies Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Advanced Enzyme Technologies Limited (hereinafter referred to as 'the Holding Company') and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Advanced Bio-Agro Tech Limited	Subsidiary
2	Advanced Enzytech Solutions Limited	Wholly Owned Subsidiary
3	Advanced Enzymes USA, Inc. ('AEU')	Wholly Owned Subsidiary
4	Advanced Supplementary Technologies Corporation	Wholly Owned Subsidiary of AEU
5	Cal India Foods International ('CAL')	Wholly Owned Subsidiary of AEU
6	Enzyme Innovation, Inc	Wholly Owned Subsidiary of CAL

MSKA & ASSOCIATES LLP Chartered Accountants

7	JC Biotech Private Limited	Subsidiary
8	Scitech Specialities Private Limited	Subsidiary
9	Advanced Enzymes Europe B.V. ('AEEBV')	Wholly Owned Subsidiary
10	Evoxx Technologies GmbH	Wholly Owned Subsidiary of AEEBV
11	Saiganesh Enzytech Solutions Private Limited	Subsidiary
12	Starya Labs Inc.	Wholly Owned Subsidiary of AEU
13	Advanced Nutrazyme Private Limited	Wholly Owned Subsidiary (with effect from July 04, 2025)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of four subsidiaries included in the Statement, whose interim financial information (before consolidation adjustment) reflects total revenues of Rs. 601.80 million, total net profit after tax of Rs. 24.90 million and total comprehensive income of Rs. 24.92 million, for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been reviewed by the other auditors whose reports have been furnished to us by the Management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.

7. One Subsidiary is located outside India whose interim financial information has been prepared in accordance with the accounting principles generally accepted in their respective country and which has been reviewed by other auditor under generally accepted auditing standards applicable in their respective country. The Holding Company's Management has converted the interim financial information of such subsidiary located outside India from accounting principles generally accepted in their respective country to accounting principles generally accepted in India.

   We have reviewed these conversion adjustments made by the Holding Company's Management. Our conclusion on the Statement, in so far as it relates to the interim financial information of such subsidiary located outside India is based on the report of other auditor and the conversion adjustments prepared by the Management of the Holding Company and reviewed by us.

   Our conclusion is not modified in respect of the above matter.

MSKA & ASSOCIATES LLP Chartered Accountants

8. The Statement includes the interim financial information of four subsidiaries which has not been reviewed by their auditors, whose interim financial information (before consolidation adjustment) reflects total revenue of Rs. 77.16 million, total net profit after tax of Rs. 14.09 million and total comprehensive income of Rs. 14.09 million, for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such Management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

   Our conclusion is not modified in respect of the above matter with respect to our reliance on these interim financial information certified by the Management.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

Avaidya

Amrish Vaidya
Partner
Membership No.: 101739
UDIN: 26101739KIPUEZ6689

MSKA & ASSOCIATES LLP Chartered Accountants

Place: Mumbai
Date: August 08, 2026

Advanced Enzyme Technologies Limited
CIN No.: L24200MH1989PLC051018
Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.
Tel No:91-22-41703220, Fax No: +91-22-25835159
Website: www.advancedenzymes.com, Email Id: sanjay@advancedenzymes.com

Statement of unaudited consolidated financial results for the quarter ended 30 June 2026

(₹ in million except per share data)

	Particulars	Quarter ended			Year ended
		30-Jun-26 Unaudited	31-Mar-26 Audited (refer note vi)	30-Jun-25 Unaudited	31-Mar-26 Audited
1	Revenue from operations	1,897.88	2,033.67	1,859.14	7,457.57
2	Other Income	130.21	72.28	88.50	348.32
3	**Total Income (1+2)**	**2,028.09**	**2,105.95**	**1,947.64**	**7,805.89**
4	**Expenses**				
	(a) Cost of materials consumed	545.02	559.61	439.70	1,943.12
	(b) Purchases of stock-in-trade #	0.01	0.00	-	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(48.14)	9.69	60.79	(13.61)
	(d) Employee benefits expense (refer note iv)	445.52	419.38	397.13	1,622.86
	(e) Finance costs (including exchange difference)	5.80	5.73	7.64	26.28
	(f) Depreciation and amortisation expense	98.79	101.92	96.18	400.93
	(g) Other expenses	445.83	412.71	397.20	1,614.54
	Total Expenses	**1,492.83**	**1,509.04**	**1,398.64**	**5,594.12**
5	**Profit before exceptional item and tax (3-4)**	**535.26**	**596.91**	**549.00**	**2,211.77**
6	Exceptional item (charge / (credit)) (refer note ix & x)	-	(1.13)	-	(113.59)
7	**Profit before tax (5-6)**	**535.26**	**598.04**	**549.00**	**2,325.36**
8	Tax expense				
	Current tax	150.65	133.48	154.70	564.46
	Deferred tax charge / (credit)	(1.28)	12.04	(10.10)	24.82
	Total tax expense	**149.37**	**145.52**	**144.60**	**589.28**
9	**Net profit for the period (7-8)**	**385.89**	**452.52**	**404.40**	**1,736.08**
10	**Other comprehensive income**				
	A (i) Items that will not be reclassified to profit or loss				
	Remeasurements of defined benefit liability/(asset)	0.02	6.05	(0.57)	13.40
	(ii) Income tax related to items that will not be reclassified to profit or loss	(0.01)	(1.50)	0.16	(3.37)
	B (i) Items that will be reclassified to profit or loss				
	Exchange differences in translating financial statements of foreign operations	(14.28)	474.78	38.12	938.08
	(ii) Income tax related to items that will be reclassified to profit or loss	-	-	-	-
	Total Other comprehensive income	**(14.27)**	**479.33**	**37.71**	**948.11**
11	**Total comprehensive income (9+10)**	**371.62**	**931.85**	**442.11**	**2,684.19**
12	**Net profit attributable to:**				
	Shareholders of the Company	370.93	429.63	399.30	1,687 19
	Non-controlling interest	14.96	22.89	5.10	48.89
13	**Other comprehensive income attributable to:**				
	Shareholders of the Company	(14.27)	479.16	37.73	947.42
	Non-controlling interest #	0.00	0.17	(0.02)	0.69
14	**Total comprehensive income attributable to:**				
	Shareholders of the Company	356.66	908.79	437.03	2.634.61
	Non-controlling interest	14.96	23.06	5 08	49.58
15	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	**223.95**	**223.85**	**223.76**	**223.85**
16	Other equity				16,095.72
17	**Earnings Per Share of ₹ 2 each (not annualized)**				
	(a) ₹ (Basic)	3.31	3.84	3.57	15.08
	(b) ₹ (Diluted)	3.31	3.84	3.57	15.06

Figures are below Rs. 0.01 Million hence disclosed as Rs. 0.00

MSKA & ASSOCIATES Chartered Accountants LLP

ADVANCED ENZYME TECHNOLOGIES LIMITED THANE

W. W. Kabra

Advanced Enzyme Technologies Limited
CIN No.: L24200MH1989PLC051018
Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.
Tel No:91-22-41703220 Fax No: +91-22-25835159
Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Notes:

(i) The above unaudited consolidated financial results include the financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Scitech Specialities Private Limited (India), Saiganesh Enzytech Solutions Private Limited (India), Advanced Nutrazyme Private Limited (India)(w.e.f. 4 July 2025), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Starya Labs, Inc. (U.S.A.), Advanced Enzymes Europe B.V. (Netherlands) and Evoxx Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".

(ii) The above unaudited consolidated financial results of the Group were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 8 August 2026. The above results have been reviewed by the statutory auditors of the Company and they have expressed an unmodified conclusion. The review report will be filed with stock exchanges and will be available on the Company's website. The above results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

(iii) The Group operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(iv) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 576,000 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 12 August 2023, approved by Nomination and Remuneration Committee of the Board. The Company has further granted 512,500 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 27 March 2025, approved by Nomination and Remuneration Committee of the Board.

(v) The Group has allotted 49,350 equity shares during the quarter ended 30 June 2026 to employees under the 'Employee Stock Option Scheme 2022' ("ESOP Scheme 2022").

(vi) The figures for the quarter ended 31 March 2026 as reported in these unaudited consolidated financial results are the balancing figures between consolidated audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

(vii) The Board of Directors in its meeting held on 9 May 2026 had proposed the final dividend for the financial year 2025-26 of Rs. 1.35/- per equity share and the same has been approved by the shareholders of the Company in its Annual General Meeting held on 31 July 2026 and paid on 5 August 2026.

(viii) The Company has incorporated a new wholly owned subsidiary by name of Advanced Nutrazyme Private Limited ('ANPL'), the subsidiary received its certificate of incorporation on 4 July 2025. ANPL will be engaged in the business of sales and distribution of the Company's Nutrition and Wellness range of products.

(ix) On November 21, 2025, the Government of India had notified the four Labour Codes – the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 – consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and Frequently Asked Questions (FAQs) to enable assessment of the financial impact due to changes in regulations.

The Group had assessed and disclosed the incremental impact of these changes on the basis of current remuneration structure. The assessment was based on the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group had presented such incremental impact under "Exceptional Items" in the consolidated financial results

The impact for the quarter ended 31 December 2025 consisting of gratuity of Rs. 45.67 million and compensated absences of Rs. 1.51 million was accounted in the consolidated financial results primarily due to change in wage definition. Further, for the quarter ended 31 March 2026, addtional impact of gratuity of Rs. 0.63 million had been recognised. The impact for the year ended 31 March 2026 pertaining to gratuity was Rs. 46.30 million and compensated absences is Rs. 1 51 million.

(x) On 22 August 2025, United States court of appeals had directed the District of Arizona to pass the order in favour of Advanced Supplementary Technologies Corporation (U.S.A.) ("AST") wholly owned subsidiary of Advanced Enzyme USA, Inc. (U.S.A.) for the lawsuit filed by the Competitor. Based on the above direction of United States Court of Appeals and legal opinion received in the quarter ended 31 December 2025, the provision created amounting to Rs 159.64 million earlier with respect to the mentioned lawsuit was reversed. Further, for the quarter ended 31 March 2026, addtional impact of Rs. 1.75 million had been recognised on account of foreign exchange fluctuation. The cumulative impact for the year ended 31 March 2026 pertaining to the above mentioned lawsuit is Rs. 161.39 million

By Order of the Board of Directors
For Advanced Enzyme Technologies Limited
CIN No.: L24200MH1989PLC051018

M.M. Kabra

M.M. Kabra
Wholetime Director
DIN : 00148294

MSKA & ASSOCIATES LLP Chartered Accountants

Place: Thane
Dated: 8 August 2026

ADVANCED ENZYME TECHNOLOGIES LIMITED THANE

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

HO
602, Floor 6, Raheja Titanium
Western Express Highway, Geetanjali
Railway Colony, Ram Nagar, Goregaon (E)
Mumbai 400063, INDIA
Tel: +91 22 6974 0200

Independent Auditor's Review Report on Standalone unaudited financial results of Advanced Enzyme Technologies Limited for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Advanced Enzyme Technologies Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Advanced Enzyme Technologies Limited (hereinafter referred to as 'the Company') for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

Amrish Vaidya
Partner
Membership No.: 101739
UDIN: 26101739ZKQVHQ7374

MSKA & ASSOCIATES LLP Chartered Accountants

Place: Mumbai
Date: August 08, 2026

Advanced Enzyme Technologies Limited
CIN No. L24200MH1989PLC051018
Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.
Tel No 91-22-41703220 Fax No. +91-22-25835159
Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Statement of Unaudited standalone financial results for the quarter ended 30 June 2026

(Rs in Million except per share data)

	Particulars	Quarter ended			Year ended
		30-Jun-26 Unaudited	31-Mar-26 Audited (Refer note V)	30-Jun-25 Unaudited	31-Mar-26 Audited
1	Revenue from operations	1,158.57	1,164.10	1,250.24	4,527.66
2	Other Income	22.87	51.63	538.52	633.88
3	**Total Income (1+2)**	**1,181.44**	**1,215.73**	**1,788.76**	**5,161.54**
4	**Expenses**				
	(a) Cost of materials consumed	480.94	501.35	518.99	1,877.21
	(b) Changes in inventories of finished goods and work-in-progress	(65.04)	(15.27)	43.56	(30.82)
	(c) Employee benefits expense (refer note iii)	176.93	163.57	162.07	647.28
	(d) Finance costs (including exchange difference)	0.37	0.60	0.53	2.07
	(e) Depreciation and amortisation expense	29.21	31.15	29.29	120.83
	(f) Other expenses	261.62	245.90	220.36	929.65
	Total expenses	**884.03**	**927.30**	**974.80**	**3,546.22**
5	**Profit before exceptional item and tax (3-4)**	**297.41**	**288.43**	**813.96**	**1,615.32**
6	**Exceptional item (refer note viii)**	-	-	-	38.58
7	**Profit before tax (5-6)**	**297.41**	**288.43**	**813.96**	**1,576.74**
8	Tax expense				
	Current tax	66.64	67.70	74.41	270.69
	Deferred tax charge/(credit)	7.31	(2.22)	(0.26)	(12.01)
	Total tax expense	**73.95**	**65.48**	**74.15**	**258.68**
9	**Net profit for the period (7-8)**	**223.46**	**222.95**	**739.81**	**1,318.06**
10	**Other comprehensive income**				
	A (i) Items that will not be reclassified to Profit or Loss				
	Remeasurements of defined benefit liability/(asset)	-	6.04	-	11.27
	(ii) Income tax related to items that will not be reclassified to Profit or Loss	-	(1.52)	-	(2.84)
	B (i) Items that will be reclassified to Profit or Loss	-	-	-	-
	(ii) Income tax related to items that will be reclassified to Profit or Loss	-	-	-	-
	Total Other comprehensive income	-	**4.52**	-	**8.43**
11	**Total comprehensive income (9+10)**	**223.46**	**227.47**	**739.81**	**1,326.49**
12	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	**223.95**	**223.85**	**223.76**	**223.85**
13	Other equity				**6,872.38**
14	**Earnings Per Share of ₹ 2 each (not annualized)**				
	(a) ₹ (Basic)	2.00	1.99	6.61	11.78
	(b) ₹ (Diluted)	1.99	1.99	6.61	11.76

MSKA & ASSOCIATES LLP Chartered Accountants

ADVANCED ENZYME TECHNOLOGIES LIMITED THANE

Advanced Enzyme Technologies Limited
CIN No.: L24200MH1989PLC051018
Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.
Tel No:91-22-41703220 Fax No: +91-22-25835159
Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Notes:

(i) The above unaudited standalone financial results of Advanced Enzyme Technologies Limited ('the Company') were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 8 August 2026. The above results have been subjected to 'Limited Review' by the statutory auditors of the Company and they have expressed an unmodified conclusion. The limited review report will be filed with stock exchanges and will be available on the Company's website. The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies in India.

(ii) The Company operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(iii) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 576,000 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 12 August 2023, approved by Nomination and Remuneration Committee of the Board. The Company has further granted 512,500 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 27 March 2025, approved by Nomination and Remuneration Committee of the Board.

(iv) The Company has allotted 49,350 equity shares during the quarter ended 30 June 2026 to employees under the 'Employee Stock Option Scheme 2022' ("ESOP Scheme 2022").

(v) The figures for the quarter ended 31 March 2026 as reported in these unaudited standalone financial results are the balancing figures between standalone audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit

(vi) The final dividend for the financial year 2025-26 of Rs 1.35/- per equity share is paid on 5 August 2026 after approval of the shareholders of the Company in its Annual General Meeting held on 31 July 2026

(vii) The Company has incorporated a new wholly owned subsidiary by name of Advanced Nutrazyme Private Limited ('ANPL'), the subsidiary received its certificate of incorporation on 4 July 2025. ANPL will be engaged in the business of sales and distribution of the Company's Nutrition and Wellness range of products.

(viii) On 21 November 2025, the Government of India notified the four Labour Codes – the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 – consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and Frequently Asked Questions (FAQs) to enable assessment of the financial impact due to changes in regulations.

The Company had assessed and disclosed the incremental impact of these changes on the basis of current remuneration structure. Based on our assessment and the information available, consistent with the guidance provided by the Institute of Chartered Accountants of India and considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company presented such incremental impact under "Exceptional Items" in the standalone financial results for the year ended 31 March 2026. The incremental impact consisting of gratuity of Rs. 38.58 million primarily arose due to change in wage definition.

MSKA & Associates Chartered Accountants LLP

ADVANCED ENZYME TECHNOLOGIES LIMITED THANE

By Order of the Board of Directors
For Advanced Enzyme Technologies Limited
CIN: L24200MH1989PLC051018

M. M. Kabra

M. M. Kabra
Wholetime Director
DIN 00148294

Place: Thane
Dated: 8 August 2026

advanced enzymes
Where ENZYME is Life

Advanced Enzyme Technologies Ltd.
CIN: L24200MH1989PLC051018
Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India
Tel: +91-22-4170 3200
Email: info@advancedenzymes.com, www.advancedenzymes.com

Annexure – II

Details pertaining to Buyback of Equity Shares of the Company

Number of securities proposed for buyback Number of securities proposed for buyback as a percentage of existing paid up capital	Considering the Maximum Buyback Size and the Maximum Buyback Price as defined above, the indicative Maximum number of Equity Shares proposed to be bought back is 1,394,000 (i.e. 1.24% of the existing paid up capital of the Company). If the Equity Shares are bought back at a price lower than the Maximum Buyback Price, then the actual number of Equity Shares bought back will exceed the indicative number of Equity Shares proposed to be bought back.
Buyback price	Maximum Buyback price – at a price not exceeding ₹ 500 per Equity Share
Actual securities in number and percentage of existing paid up capital bought back	The actual number of securities and percentage of the existing paid-up capital bought back shall be determined after completion of the buyback.
Pre & Post shareholding pattern	As mentioned below

Pre & Post shareholding pattern

Sr. No.	Category of Shareholders	Pre Buyback (as on July 31, 2026)		Post Buyback*	
		Number of Equity Share held	% to the existing Equity Share capital	Number of Equity Share held	% to the existing Equity Share capital
A	Promoter and Promoter Group	48,419,510	43.24	48,419,510	43.79
B	Public Shareholders	63,556,640	56.76	62,162,640	56.21
	Total	**111,976,150**	**100**	**110,582,150**	**100**

* Assuming the Buy-back of Maximum Buy-back Shares, i.e. 1,394,000 Equity Shares, at the Maximum Buy-back Price, i.e. ₹ 500/- per Equity Share. The actual shareholding pattern post Buy-back may vary depending upon the actual number of Equity Shares bought back under the Buy-back.

ADVANCED ENZYME TECHNOLOGIES LIMITED
THANE

advanced enzymes
Where ENZYME is Life

Advanced Enzyme Technologies Ltd.
CIN: L24200MH1989PLC051018
Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India
Tel: +91-22-4170 3200
Email: info@advancedenzymes.com, www.advancedenzymes.com

Annexure – III

Details pertaining to acquisition of remaining stake of JCB and infusion of additional funds in ANPL

a)	Name of the target entity, details in brief such as size, turnover etc.	JC Biotech Private Limited, existing Subsidiary of the Company with 95.72% holding. Turnover of JCB for FY 2026 was ₹ 728 million	Advanced Nutrazyme Private Limited existing Wholly Owned Subsidiary of the Company. Turnover of ANPL for FY 2026 was ₹ 0.02 million
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No, the transaction does not fall within the definition of the related party transaction under the SEBI Listing Regulations except to the extent of acquisition of the Equity Shares from Mr. Naveenkrishna Bondalapati, who is also a Whole Time Director in JCB. The transaction, to the extent above has been approved by the Audit Committee based on the valuation report. Except to the extent of the shares held by the Company in JCB, the promoter/ promoter group/ group companies do not have any interest in JCB.	Yes, the transaction falls within the definition of the related party transaction under the SEBI Listing Regulations. However, as this transaction is between the holding company and its wholly owned subsidiary, the provisions of SEBI Listing Regulations are not applicable. Except to the extent of the shares held by the Company in ANPL, the promoter/ promoter group/ group companies do not have any interest in ANPL.
c)	Industry to which the entity being acquired belongs	Pharmaceutical	Nutrition and wellness
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To make JCB a Wholly Owned Subsidiary and thereby optimizing synergies across business operations at the consolidated level.	To further infuse funds in ANPL by way of Equity investment and/or inter corporate deposit, to be utilized by it for its business and/or general corporate purposes.

THANE

advanced enzymes
Where ENZYME is Life

Advanced Enzyme Technologies Ltd.
CIN: L24200MH1989PLC051018
Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India
Tel: +91-22-4170 3200
Email: info@advancedenzymes.com, www.advancedenzymes.com

e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable	Not Applicable
f)	Indicative time period for completion of the acquisition	September 30, 2026	December 31, 2027
g)	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration	Cash Consideration
h)	cost of acquisition and/or the price at which the shares are acquired	₹ 90 per Equity Share (Total Consideration - ₹ 79.79 million)	Infusion of additional funds up to ₹ 20 million, in one or more tranches.
i)	Percentage of shareholding / control acquired and / or number of shares acquired	886,544 Equity Shares (4.28%). Upon completion of this acquisition, JCB will become a Wholly Owned Subsidiary of the Company	The Company will continue to hold 100% Equity Shares of ANPL.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	JCB is in the business of manufacturing and sale of Bio Pharmaceuticals through the process of aerobic fermentation. It was incorporated on December 31, 1991 (acquired in 2016). The last 3 years turnover for FY 26, FY 25 and FY 24 was ₹ 728 million, ₹ 600 million and ₹ 627 million respectively. JCB has its presence in India.	ANPL is in the business of marketing and selling of nutraceutical products. It was incorporated on July 04, 2025. The revenue for FY 26 was ₹ 0.02 million and the revenue for earlier years is not applicable. ANPL has its presence in India.

ADVANCED ENZYME TECHNOLOGIES LIMITED
THANE